VCIM
ADMA icon

Velan Capital Investment Management’s ADMA Biologics ADMA Stock Holding History

Velan Capital Investment Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,528,601
Closed -$10.1M – 18
2024
Q1 		$10.1M Sell
1,528,601
-607,499
-28% -$3.32M 4.58% 7
2023
Q4 		$9.66M Buy
2,136,100
+400,000
+23% +$1.48M 5.64% 4
2023
Q3 		$6.22M Sell
1,736,100
-989,951
-36% -$3.81M 5.01% 5
2023
Q2 		$10.1M Sell
2,726,051
-1,273,949
-32% -$4.72M 9.34% 2
2023
Q1 		$13.2M Hold
4,000,000
– – 11.29% 2
2022
Q4 		$15.5M Sell
4,000,000
-1,269,155
-24% -$3.91M 13.71% 2
2022
Q3 		$12.8M Sell
5,269,155
-804,443
-13% -$1.93M 12.7% 4
2022
Q2 		$12M Buy
6,073,598
+250,800
+4% +$493K 12.2% 3
2022
Q1 		$10.7M Buy
5,822,798
+425,000
+8% +$663K 9.89% 3
2021
Q4 		$7.61M Buy
+5,397,798
New +$7.1M 5.91% 6

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Velan Capital Investment Management's ADMA Position: Q2 2024 in Review

Velan Capital Investment Management sold out of ADMA Biologics (ADMA) in Q2 2024, closing a stake of 1,528,601 shares — an estimated $10.1M sold.

Velan Capital Investment Management first reported a position in ADMA in Q4 2021 and held it in 10 quarters. The position peaked at $15.5M in Q4 2022. 252 funds tracked by Wall St. Rank hold ADMA as of Q2 2024.

  • Velan Capital Investment Management reported no remaining ADMA Biologics position as of Q2 2024 after selling out during the quarter.
  • Velan Capital Investment Management sold 1,528,601 ADMA Biologics shares in Q2 2024, an estimated $10.1M.
  • Velan Capital Investment Management first reported a position in ADMA Biologics in Q4 2021 and held it in 10 quarters.
  • Velan Capital Investment Management's ADMA Biologics position peaked at $15.5M in Q4 2022.
  • 252 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2024.

Based on Velan Capital Investment Management's 13F filing for Q2 2024, filed 14 Aug 2024.